The impact of shigellosis and recommended treatment in children

Active Cooperative Agreement Awarded Last action

Award ID
U01AI179562
Recipient
Awarding agency
Obligated
$1,836,585

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 24% complete
Place of performance
Baltimore, MD 21205, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Shigella is a primary cause of moderate-to-severe diarrhea in children living in impoverished areas of the world. Shigella is known for causing dysentery (blood in the stool). However, majority of the children infected with shigella present with watery diarrhea. The current world health organization (who) guidelines for treatment of shigellosis recommend treatment with antibiotics in the presence of visible blood in the stool. Thus, the non- dysentery shigella associated watery diarrhea (NDSD) cases would not be treated with antibiotics. The absence of dysentery does not necessarily indicate a low risk of death and does not rule out shigella as a cause of diarrhea. In particularly vulnerable younger children or with malnutrition, identification and treatment of shigella infection might be lifesaving. Consequently, a critical question remains to be answered. Should cases of NDSD be treated with antibiotics? IT may be hypothesized that these cases, if identified quickly, should be treated with antibiotics to reduce clinical severity, improve intestinal pathology, improve long-term developmental potential, and even reduce mortality. Identification of such cases will require a rapid test to document these infections so that treatment can be initiated promptly and is evidence based. And zambia. To address these critical questions, we will carry out a randomized placebo controlled clinical trial in bangladesh to determine if antibiotic treatment of NDSD cases in children will improve clinical outcomes, GUT health, and growth in children. In addition, we will introduce a novel, simple, and rapid test "rldt" for the detection of shigella that has been field tested and shown to be applicable to health care facilities in resource poor endemic countries. We will assess the acceptability and feasibility of implementation of the rldt assay. This study will help determine if there is a need for policy change for the treatment of NDSD with antibiotics. Importantly, this study will validate the need for a rapid test capable of identifying patients who will benefit from antibiotics.

Transactions

Action Obligated Date
Amendment $668,844
Amendment $0
Amendment $195,150
Amendment $209,753
Original award $762,838

Subawards

Subrecipient Amount Awarded
University Of Washington The John Hopkins University (JHU) serving as PI. Dr. Pavlinac will provide guidance on the study design, protocol, as well as review of data collection and… $72,887
International Centre For Diarrhoeal Disease Research, Bangladesh Screening, consenting and enrollment of children under 5. Laboratory processing and testing. Weekly field visits / follow up visits. $209,753
Centre For Infectious Disease Research In Zambia • The sub-recipient will screen and enroll study participants and follow up with twice weekly home visits for three months. They will collect data and… $195,150

Quick answers

Who received award U01AI179562?

U01AI179562 was awarded to The Johns Hopkins University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 2, 2025.

How much is award U01AI179562 worth?

$1,836,585 has been obligated on U01AI179562.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login